UK-based binx health has collaborated with McKesson, a global healthcare company, for the sale and distribution of the binx io platform in the US, it was reported on Tuesday.

The binx io is an FDA approved infectious disease platform that provides results in about thirty minutes and allows diagnosis and treatment of chlamydia and gonorrhoea to take place in a single visit. It has demonstrated to be on par with central-laboratory testing. It is also likely to be used in satellite point-of-care settings designated under such moderate or high complexity certificates.

Jeffrey Luber, binx health's chief executive officer, stated: "At binx we consider evidence-based care and consumer convenience central to all we do. Today's announcement is a win-win-win for clinics, patients and the public health and we are especially proud of this new distribution partnership for national reach."